Bumpy ride for BTG and Astra after trials failure
AstraZeneca and BTG yesterday axed plans to develop a new drug to treat severe blood poisoning after it failed medical trials.
Stage II trials comparing doses of the duo's CytoFab treatment with placebo drugs in patients with severe septicaemia or septic shock "did not show any significant improvements versus the placebo", the firms admitted.
As a result, the drug has been shelved, leaving BTG, led by Louise Makin, with a £28m charge for this financial year. Its shares were knocked back in early trading, although by the end of the day the stock had recovered. AstraZeneca shares lost 61p to 3015p but most of that was because its dividend was being paid out yesterday.
Look beyond the usual shows for the best festive telly
Geoffrey Macnab does not like the comedian's big screen debut
The battle for control of Stieg Larsson's £30m legacy
French pub fined €9,000 after customers returned empties to bar - because it's 'undeclared labour'
David Cameron takes his biggest gamble yet as he gets tough on Europe over immigration
Two PAs cleared of fraud - and Nigella Lawson left reeling at 'ridiculous sideshow' of drug allegations and public dissection of her marriage to Charles Saatchi
Burglar steals video tapes of child abuse, hands them into police
Paul Walker's daughter Meadow attends Justin Bieber Believe premiere
- 1 Tim Sherwood challenges Daniel Levy to set out vision for Tottenham Hotspur’s future
- 2 French pub fined €9,000 after customers returned empties to bar - because it's 'undeclared labour'
- 3 Sun will 'flip upside down' within weeks, says Nasa
- 4 #Teamnigella: It’s the only side to be on
- 5 Christmas comes early: Justin Bieber is 'retiring from music'
- < Previous
- Next >
iJobs Money & Business
£59999 - £80001 per annum + Benefits: Pro-Recruitment Group: A Top 10 firm in ...
£50000 - £75000 per annum + benefits + bonus: Harrington Starr: Project Manage...
£60000 - £90000 per annum + benefits + bonus: Harrington Starr: Business Analy...
£Negotiable: Citifocus: High calibre individual with institutional client serv...